RedHill Biopharma (RDHL) Receivables - Other (2012 - 2025)

RedHill Biopharma (RDHL) has 5 years of Receivables - Other data on file, last reported at $3.1 million in Q4 2025.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $3.1 million in Q4 2025; TTM through Dec 2025 was $3.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.1 million, changed N/A from the prior year.
• Receivables - Other for Q4 2025 stood at $3.1 million, up from $1.3 million in the prior quarter.
• Over the last five years, Receivables - Other for RDHL reached as high as $3.1 million in Q4 2025 and fell as low as $1.3 million in Q2 2023.
• Historically, Receivables - Other has averaged $2.1 million across 3 years, with a median of $1.9 million in 2022.
• On a YoY basis, Receivables - Other climbed as much as 28.58% in 2023 and fell as far as 28.58% in 2023.
• Year by year, Receivables - Other stood at $1.9 million in 2022, then retreated by 28.58% to $1.3 million in 2023, then jumped by 134.48% to $3.1 million in 2025.
• Per Business Quant data, the three most recent Receivables - Other figures were $3.1 million in Q4 2025, $1.3 million in Q2 2023, and $1.9 million in Q2 2022.